AI assistant
TruScreen Group Limited — Board/Management Information 2018
Sep 21, 2018
66285_rns_2018-09-21_d8427d59-fa13-465d-824b-42a379801d74.pdf
Board/Management Information
Open in viewerOpens in your device viewer
NZX and Media Release 21 September 2018
NZX Limited
WELLINGTON
Withdrawal of Nomination
TruScreen Limited (NZAX: TRU)
Cervical cancer technology company, TruScreen Limited (NZAX:TRU) announces that Ms Marie Ficarra has, for personal reasons, withdrawn her nomination for election as a director of the company at the Annual Meeting on 27 September 2018.
As a result, Resolution 5 in the Notice of Meeting has been withdrawn and Marie will cease to be a director at the close of the Annual Meeting.
The Board would like to acknowledge and thank Marie for her contribution to the Company during her time as a Director.
Martin Dillon
CEO
-ENDS-
For more information visit www.truscreen.com
Contact Martin Dillon
TruScreen Chief Executive Officer
Email: [email protected]
About TruScreen:
TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.
==> picture [286 x 179] intentionally omitted <==